2nd World Congress on
Controversies in the Management of Viral Hepatitis (C-Hep)
Berlin, Germany, October 18-20, 2012 |
|
| |
| Preliminary Scientific Program |
 |
|
|
Thursday, October 18, 2012 |
|
14:00-16:00 |
|
|
Moderators: Jürgen Rockstroh, Germany & Jonathan Schapiro, Israel |
|
14:00-14:05 |
Chairpersons Congress Welcome Address |
|
14:05-14:30 |
HCV in 2020: Any cases left? Rafael Esteban, Spain |
|
14:30-14:35 |
Discussion |
|
14:35-15:00 |
HCV vaccine: Where do we stand? Ulrich Spengler , Germany |
|
15:00-15:05 |
Discussion |
|
Interferon-free HCV therapy: Are we getting there? |
|
15:05-15:25 |
No: Graham Foster, UK |
|
15:25-15:45 |
Yes: Heiner Wedemeyer, Germany |
|
15:45-16:00 |
Discussion |
| |
|
|
16:00-17:00 |
Pipeline Showcase: New Drugs on the Horizon |
| |
|
|
17:00-17:30 |
Coffee Break and Poster Exhibition |
| |
|
|
17:30-18:45 |
Janssen Satellite Symposium |
| |
|
|
18:45-20:00 |
Welcome Reception and Poster Prize Ceremony |
|
|
|
|
Moderators: Stefan Zeuzem, Germany & Eckart Schott, Germany |
|
09:00-09:05 |
Overview of HCV sessions by HCV Program Director
Stefan Zeuzem , Germany |
|
|
Direct Antivirals: How have the treatment paradigms changed? |
|
|
Moderators Introduction |
|
HCV Direct Acting Antivirals: |
|
09:10-09:30 |
In treatment naïve: Stanislas Pol, France |
|
09:30-09:50 |
In treatment experienced: Thomas Berg, Germany |
|
09:50-10:10 |
Toxicity management: Christoph Hezode, Paris |
|
10:10-10:40 |
Drug-drug interactions: David Back, UK |
|
10:40-11:00 |
Panel discussion |
| |
|
|
11:00-11:30 |
Coffee Break |
|
|
|
SESSION 3: Do we need to know genetic factors such as IL28B for treatment decision making? |
HALL A | |
|
11:30-11:45 |
Yes: Vincent Soriano, Spain |
|
11:45-12:00 |
No: Mathew Albert, France |
|
12:00-12:15 |
Discussion |
|
|
| SESSION 4: HCV therapy is for specialists only? |
HALL B | |
|
11:30-11:45 |
|
|
11:45-12:00 |
No: Michael Biermer, Germany |
|
12:00-12:15 |
Discussion |
| |
|
|
12:15-13:00 |
Lunch Break |
| |
|
|
13:00-14:15 |
Merck Sharp & Dohme Satellite Symposium
Successful HCV Treatment in the Real World: Lessons From Clinical Practice |
|
13:00-13:05 |
Welcome and Opening Remarks: Jürgen Rockstroh, Germany |
|
13:05-13:20 |
Emerging Evidence Guiding Clinical Practice: Christoph Sarrazin, Germany |
|
13:20-13:40 |
Managing Adverse Events in the Clinical Setting: Jean Michel Pawlotsky, France |
|
13:40-14:00 |
Protease Inhibitors in Practice:Case Studies: Geoffrey Dusheiko, UK |
|
14:00-14:10 |
Panel Discussion |
|
14:10-14:15 |
Closing Remarks: Jürgen Rockstroh, Germany |
|
|
|
SESSION 5: Patients should wait for DAA combination therapy |
HALL A | |
|
14:15-14:30 |
Yes: Patrick Ingiliz, Germany |
|
14:30-14:45 |
No: Geoffrey Dusheiko, UK |
|
14:45-15:00 |
Discussion |
|
|
|
SESSION 6: Resistance to HCV Protease Inhibitors: Game over? |
HALL B | |
|
14:15-14:30 |
Yes: Jean Michel Pawlotsky , France |
|
14:30-14:45 |
No: Christoph Sarrazin, Germany |
|
14:45-15:00 |
Discussion |
|
15:00-15:30 |
|
SESSION 7: Interactive Case Session |
HALL A | |
|
|
How to treat HCV relapse after OLTX |
|
|
|
|
|
|
SESSION 8: Interactive Case Session
Supported by an unrestricted grant from Boehringer Ingelheim |
HALL B | |
|
|
How to treat HCV in HIV coinfection |
|
|
Stefan Mauss, Germany |
| |
|
|
15:30-16:00 |
Coffee Break |
|
16:00-17:30 |
|
|
16:00-16:20 |
Fatty liver disease: what do we know?
Claus Niederau, Germany |
|
16:20-16:40 |
Vitamin D and liver disease: Which role does it play?
Christian M. Lange, Germany |
|
16:40-17:00 |
End-stage liver disease: What is new?
Marion Peters, USA |
|
17:00-17:20 |
Treatment of HCC: state of the Art:
|
|
17:20-17:30 |
Panel Discussion |
|
Saturday, October 20, 2012 |
|
|
| PLENARY SESSION 10: HBV THERAPY IN 2012 |
HALL A | |
|
Moderators: Fabien Zoulim, France & Jörg Petersen, Germany |
|
08:30-08:35 |
Overview of HBV sessions by HBV Program Director: Fabien Zoulim, France |
|
08:35-09:00 |
Hepatitis B Therapy: State of the Art and open challenges: Jörg Petersen, Germany |
|
Is there a need for combination therapy? |
|
09:00-09:15 |
Yes: Florian van Boemmel, Germany |
|
09:15-09:30 |
No: Maria Buti, Spain |
|
09:30-09:50 |
HBV preventive and therapeutic vaccines: What is new? Marie-Louise Michel, France |
| 09:50-10:10 |
Hepatitis Delta: What is new? Heiner Wedemeyer, Germany |
|
10:10-10:30 |
Panel Discussion |
| |
|
|
10:30-11:00 |
Coffee Break |
|
|
PLENARY SESSION 11: Interactive Case Session
Supported by an unrestricted grant from Gilead Sciences Europe Ltd. |
HALL A |
|
|
Moderator: Fabien Zoulim , France |
|
The challenging hepatitis B case |
|
|
Mark Nelson, UK |
|
|
Karine Lacombe, France |
|
|
| PLENARY SESSION 12 |
HALL A | |
|
11:45-12:00 |
Strategies to prevent HCC: What can we do? Mark Thursz, UK |
|
12:00-12:15 |
Can we afford HCV DAAs for all? Maud Lemoine, France |
|
12:15-12:45 |
What are the remaining challenges in hepatitis research? Michael Manns, Germany |
|
|
|
|
WebStudio.co.il